Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair.
10.3724/zdxbyxb-2023-0256
- Author:
Fujing GE
1
;
Xiangning LIU
2
;
Hongyu ZHANG
2
;
Tao YUAN
2
;
Hong ZHU
2
;
Bo YANG
2
;
Qiaojun HE
3
Author Information
1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. 3160105302@zju.edu.cn.
2. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
3. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. qiaojunhe@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
DNA damage repair;
Deubiquitinating enzyme;
Drug sensitivity;
Non-small cell lung carcinoma
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Antineoplastic Agents/pharmacology*;
Lung Neoplasms/genetics*;
DNA Damage;
DNA;
Deubiquitinating Enzymes/genetics*
- From:
Journal of Zhejiang University. Medical sciences
2023;52(5):533-543
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To investigate the effects and mechanisms of deubiquitinating enzyme Josephin domain containing 2 (JOSD2) on susceptibility of non-small cell lung carcinoma (NSCLC) cells to anti-cancer drugs.
METHODS:The transcriptome expression and clinical data of NSCLC were downloaded from the Gene Expression Omnibus. Principal component analysis and limma analysis were used to investigate the deubiquitinating enzymes up-regulated in NSCLC tissues. Kaplan-Meier analysis was used to investigate the relationship between the expression of deubiquitinating enzymes and overall survival of NSCLC patients. Gene ontology enrichment and gene set enrichment analysis (GSEA) were used to analyze the activation of signaling pathways in NSCLC patients with high expression of JOSD2. Gene set variation analysis and Pearson correlation were used to investigate the correlation between JOSD2 expression levels and DNA damage response (DDR) pathway. Western blotting was performed to examine the expression levels of JOSD2 and proteins associated with the DDR pathway. Immunofluorescence was used to detect the localization of JOSD2. Sulforhodamine B staining was used to examine the sensitivity of JOSD2-knock-down NSCLC cells to DNA damaging drugs.
RESULTS:Compared with adjacent tissues, the expression level of JOSD2 was significantly up-regulated in NSCLC tissues (P<0.05), and was significantly correlated with the prognosis in NSCLC patients (P<0.05). Compared with the tissues with low expression of JOSD2, the DDR-related pathways were significantly upregulated in NSCLC tissues with high expression of JOSD2 (all P<0.05). In addition, the expression of JOSD2 was positively correlated with the activation of DDR-related pathways (all P<0.01). Compared with the control group, overexpression of JOSD2 significantly promoted the DDR in NSCLC cells. In addition, DNA damaging agents significantly increase the nuclear localization of JOSD2, whereas depletion of JOSD2 significantly enhanced the sensitivity of NSCLC cells to DNA damaging agents (all P<0.05).
CONCLUSIONS:Deubiquitinating enzyme JOSD2 may regulate the malignant progression of NSCLC by promoting DNA damage repair pathway, and depletion of JOSD2 significantly enhances the sensitivity of NSCLC cells to DNA damaging agents.
